OTC Markets OTCPK - Delayed Quote ? USD ONDINE BIOMEDICAL INC (OBIMF) Follow Compare 0.1100 0.0000 (0.00%) As of November 6 at 3:00 PM EST. Market Open. All News Press Releases SEC Filings All SEC Filings Corporate Changes & Voting Matters Periodic Financial Reports Proxy Statements Tender Offer/Acquisition Reports Offering Registrations Ondine accelerates pivotal antimicrobial trial after $11m financing Ondine’s Phase III trial will investigate its Steriwave system for nasal photodisinfection before surgery. Clinical Trials Arena ? 2 days ago OBIMF 0.00% M?lnlycke and Ondine join forces against HAIs M?lnlycke Health Care partners with Ondine for Steriwave distribution collaboration in the key markets of the UK, Europe and the Middle East. PR Newswire ? last month OBIMF 0.00% Ondine Biomedical’s nasal photodisinfection named as leading photonics biomedical technology for its potential to safely combat AMR VANCOUVER, British Columbia, November 13, 2023--Ondine Biomedical’s Steriwave nasal photodisinfection technology has been shortlisted in the biomedical category of the 2024 international society for optics and photonics SPIE Prism Awards. Ondine’s nasal photodisinfection technology, which has been significantly reducing hospital acquired infections, uses a combination of a photosensitive agent and red laser light to eliminate bacteria, viruses, and fungi in the nose in minutes without generating Business Wire ? 11 months ago OBI.L Performance Overview Trailing total returns as of 11/7/2024, which may include dividends or other distributions. Benchmark is FTSE 100 Return OBIMF FTSE 100 YTD -56.00% -1.77% 1-Year -56.00% -1.77% 3-Year -56.00% -1.77%
